Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12042618rdf:typepubmed:Citationlld:pubmed
pubmed-article:12042618lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C0332835lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C0036186lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C1522318lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C0042402lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C0042523lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C0221198lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C0199176lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C1948041lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C0332152lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C0522523lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C0597635lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:12042618lifeskim:mentionsumls-concept:C1550147lld:lifeskim
pubmed-article:12042618pubmed:issue6lld:pubmed
pubmed-article:12042618pubmed:dateCreated2002-6-3lld:pubmed
pubmed-article:12042618pubmed:abstractTextIntragraft verapamil is effective in treating no-reflow during saphenous vein graft (SVG) percutaneous coronary intervention (PCI). In this study, we assessed the use of intragraft verapamil given pre-PCI to prevent no-reflow.lld:pubmed
pubmed-article:12042618pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12042618pubmed:languageenglld:pubmed
pubmed-article:12042618pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12042618pubmed:citationSubsetIMlld:pubmed
pubmed-article:12042618pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12042618pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12042618pubmed:statusMEDLINElld:pubmed
pubmed-article:12042618pubmed:monthJunlld:pubmed
pubmed-article:12042618pubmed:issn1042-3931lld:pubmed
pubmed-article:12042618pubmed:authorpubmed-author:GibsonC...lld:pubmed
pubmed-article:12042618pubmed:authorpubmed-author:ChouTony MTMlld:pubmed
pubmed-article:12042618pubmed:authorpubmed-author:MichaelsAndre...lld:pubmed
pubmed-article:12042618pubmed:authorpubmed-author:ApplebyMarkMlld:pubmed
pubmed-article:12042618pubmed:authorpubmed-author:OttenMatthew...lld:pubmed
pubmed-article:12042618pubmed:authorpubmed-author:DautermanKent...lld:pubmed
pubmed-article:12042618pubmed:authorpubmed-author:PortsThomas...lld:pubmed
pubmed-article:12042618pubmed:issnTypePrintlld:pubmed
pubmed-article:12042618pubmed:volume14lld:pubmed
pubmed-article:12042618pubmed:ownerNLMlld:pubmed
pubmed-article:12042618pubmed:authorsCompleteYlld:pubmed
pubmed-article:12042618pubmed:pagination299-302lld:pubmed
pubmed-article:12042618pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:meshHeadingpubmed-meshheading:12042618...lld:pubmed
pubmed-article:12042618pubmed:year2002lld:pubmed
pubmed-article:12042618pubmed:articleTitlePretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial.lld:pubmed
pubmed-article:12042618pubmed:affiliationUniversity of California at San Francisco Medical Center, Division of Cardiology, 505 Parnassus Avenue, Box 0124, San Francisco, CA 94143-0124, USA. andrewm@itsa.ucsf.edulld:pubmed
pubmed-article:12042618pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12042618pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12042618pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12042618lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12042618lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12042618lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12042618lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12042618lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12042618lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12042618lld:pubmed